The latest price target for Citius Oncology (NASDAQ:CTOR) was reported by EF Hutton on August 13, 2024. The analyst firm set a price target for $6.00 expecting CTOR to rise to within 12 months (a possible 231.49% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Citius Oncology (NASDAQ:CTOR) was provided by EF Hutton, and Citius Oncology maintained their buy rating.

There is no last upgrade for Citius Oncology

There is no last downgrade for Citius Oncology.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Citius Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Citius Oncology was filed on August 13, 2024 so you should expect the next rating to be made available sometime around August 13, 2025.

While ratings are subjective and will change, the latest Citius Oncology (CTOR) rating was a maintained with a price target of $6.00 to $6.00. The current price Citius Oncology (CTOR) is trading at is $1.81, which is out of the analyst’s predicted range.